secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001157523-23-000181
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Aldeyra's NDA for reproxalap for dry eye disease; PDUFA Nov 23, 2023
--------------------------------------------------------------------------------

- FDA accepted NDA for reproxalap, a first-in-class RASP modulator, for signs and symptoms of dry eye disease.
- PDUFA target action date set for November 23, 2023.
- FDA noted no filing review issues identified and no advisory committee meeting currently planned.
- NDA supported by five adequate and well-controlled trials; reproxalap studied in over 2,000 patients with no major safety concerns.
- Aldeyra believes reproxalap could address need for rapid, durable therapy for dry eye patients dissatisfied with current options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323000181/0001157523-23-000181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323000181/a53304873.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer